Skip to main navigation
Skip to search
Skip to main content
University of Birmingham Home
Help & FAQ
Home
Research output
Profiles
Research units
Projects
Activities
Datasets
Equipment
Prizes
Press/Media
Search by expertise, name or affiliation
Profile of neratinib and its potential in the treatment of breast cancer
Katharina Feldinger, Anthony Kong
Cancer and Genomic Sciences
Research output
:
Contribution to journal
›
Article
›
peer-review
54
Citations (Scopus)
541
Downloads (Pure)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Profile of neratinib and its potential in the treatment of breast cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Breast Cancer Treatment
100%
Neratinib
100%
Clinical Trials
28%
Signaling Pathway
14%
Clinical Activity
14%
Tumor
14%
Phosphorylation
14%
Preclinical Data
14%
Solid Tumors
14%
Breast Cancer
14%
Monotherapy
14%
Human Epidermal Growth Factor Receptor 2 (HER2)
14%
Response Predictors
14%
Clinical Data
14%
Tyrosine Kinase Receptor
14%
Adenosine Triphosphate
14%
Tyrosine Kinase Activity
14%
Epidermal Growth Factor Receptor
14%
Downstream Signaling
14%
Translational Research
14%
Binding Pocket
14%
HER1
14%
Manuscript Review
14%
Preclinical Stage
14%
HER2-mutant
14%
HER2 Overexpression
14%
HER Receptors
14%
Irreversible Tyrosine Kinase Inhibitor
14%
HER4
14%
ErbB Receptor Tyrosine Kinase
14%
Pan-HER Inhibitor
14%
HER2 mutation
14%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Neratinib
100%
Epidermal Growth Factor Receptor
42%
Protein Tyrosine Kinase
28%
Clinical Trial
28%
Receptor
14%
Neoplasm
14%
Solid Malignant Neoplasm
14%
Adenosine Triphosphate
14%
Monotherapy
14%
Biological Marker
14%
Tyrosine Kinase Receptor
14%
Protein Tyrosine Kinase Inhibitor
14%